NZ627878A - P2x4 receptor antagonist - Google Patents

P2x4 receptor antagonist

Info

Publication number
NZ627878A
NZ627878A NZ627878A NZ62787813A NZ627878A NZ 627878 A NZ627878 A NZ 627878A NZ 627878 A NZ627878 A NZ 627878A NZ 62787813 A NZ62787813 A NZ 62787813A NZ 627878 A NZ627878 A NZ 627878A
Authority
NZ
New Zealand
Prior art keywords
hydrogen atom
receptor antagonist
atom
benzene
atomic bonding
Prior art date
Application number
NZ627878A
Inventor
Masatoshi Ushioda
Kunio Kobayashi
Daisuke Saito
Shogo Sakuma
Toshiyasu Imai
Kazuhide Inoue
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Publication of NZ627878A publication Critical patent/NZ627878A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The disclosure relates to a diazepine derivative represented by general formula (I), wherein the variables R1 and R2 are a hydrogen atom, etc. or R1 and R2 together with a benzene ring to which they are attached are a naphthalene ring, etc.; R3 and R4 are a hydrogen atom, etc.; R5 is a hydrogen atom, etc.; R6 and R7 are a hydrogen atom, etc.; X is C, CH or N and Y is N, NH or C (=O), provided that when X is N, Y is not N or NH and when X is C or CH, Y is not C (=O); Z is an oxygen atom or a sulfur atom; A is a benzene ring, etc.; B is NHC (=O), etc.; D is an atomic bonding, etc.; E is an atomic bonding, etc.; G is benzene which may by substituted, etc.; and m is an integer of 0 to 5.) or a pharmaceutically acceptable salt thereof, and a P2X4 receptor antagonist.
NZ627878A 2012-01-13 2013-01-10 P2x4 receptor antagonist NZ627878A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012005343 2012-01-13
PCT/JP2013/050320 WO2013105608A1 (en) 2012-01-13 2013-01-10 P2x4 receptor antagonist

Publications (1)

Publication Number Publication Date
NZ627878A true NZ627878A (en) 2016-03-31

Family

ID=48781550

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ627878A NZ627878A (en) 2012-01-13 2013-01-10 P2x4 receptor antagonist

Country Status (16)

Country Link
US (5) US9382236B2 (en)
EP (1) EP2803662B1 (en)
JP (1) JP6207399B2 (en)
KR (2) KR102140746B1 (en)
CN (4) CN108863959B (en)
AU (1) AU2013208536B2 (en)
CA (1) CA2861024C (en)
DK (1) DK2803662T3 (en)
ES (1) ES2626036T3 (en)
HK (1) HK1203191A1 (en)
IL (1) IL233592B (en)
NZ (1) NZ627878A (en)
PL (1) PL2803662T3 (en)
PT (1) PT2803662T (en)
SG (2) SG10201605325TA (en)
WO (1) WO2013105608A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861024C (en) 2012-01-13 2020-09-22 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
AU2014288116B2 (en) 2013-07-12 2018-05-17 Kyushu University P2X4 receptor antagonist
EP3020707B1 (en) * 2013-07-12 2019-08-21 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
WO2015088565A1 (en) * 2013-12-13 2015-06-18 Sunovion Pharmaceuticals Inc. P2x4 receptor modulating compounds and methods of use thereof
EP3274336A4 (en) 2015-03-24 2018-11-14 Piramal Enterprises Limited An improved process for the preparation of clobazam and its intermediate
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
EP3426245B1 (en) 2016-03-07 2022-12-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11918589B2 (en) 2016-04-28 2024-03-05 Nippon Chemiphar Co., Ltd. Medicament for treatment of multiple sclerosis
UA122819C2 (en) 2016-05-03 2021-01-06 Байєр Фарма Акцієнгезелльшафт Aromatic sulfonamide derivatives
WO2018104307A1 (en) 2016-12-09 2018-06-14 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives and their use as anatagon i sts or negative allosteric modulators of p2x4
WO2018104305A1 (en) 2016-12-09 2018-06-14 Bayer Pharma Aktiengesellschaft Field of application of the invention
WO2018210729A1 (en) 2017-05-18 2018-11-22 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives as antagonists or negative allosteric modulators of p2x4 receptor
UY37861A (en) 2017-08-28 2019-03-29 Enanta Pharm Inc ANTIVIRAL AGENTS AGAINST HEPATITIS B
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019177117A1 (en) 2018-03-14 2019-09-19 日本ケミファ株式会社 Drug for treating cough
CA3110619A1 (en) * 2018-09-03 2020-03-12 Nippon Chemiphar Co., Ltd. Medicine for diabetic peripheral neuropathy
CN112955142A (en) 2018-09-21 2021-06-11 英安塔制药有限公司 Functionalized heterocyclic compounds as antiviral agents
BR112021009854A2 (en) 2018-11-21 2021-08-17 Enanta Pharmaceuticals, Inc. heterocycles functionalized as antiviral agents
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
JP2023509452A (en) 2020-01-03 2023-03-08 バーグ エルエルシー Polycyclic Amides as UBE2K Modulators to Treat Cancer
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
US20230149421A1 (en) * 2020-03-30 2023-05-18 Universita' Di Pisa Medicament for preventing or treating irritable bowel syndrome or inflammatory bowel disease
BR112022023376A2 (en) 2020-06-30 2023-01-10 Bayer Ag USE OF PHENYLACETHAMIDES POSSESSING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF CERTAIN OCULAR DISORDERS
KR20230031307A (en) * 2020-06-30 2023-03-07 바이엘 악티엔게젤샤프트 Substituted N-phenylacetamides with P2X4 receptor antagonistic activity
US20230277552A1 (en) 2020-08-03 2023-09-07 Nippon Chemiphar Co., Ltd. Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction
WO2022049253A1 (en) 2020-09-07 2022-03-10 Bayer Aktiengesellschaft Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators
CA3220039A1 (en) 2021-06-14 2022-12-22 Jr. David St. Jean Urea derivatives which can be used to treat cancer
IT202100025124A1 (en) 2021-09-30 2023-03-30 Univ Degli Studi Di Firenze MEDICINAL PRODUCT FOR USE IN THE PREVENTION OR TREATMENT OF NOCICEPTIVE AND/OR VISCERAL PAIN
CN118019551A (en) 2021-09-30 2024-05-10 日本化学药品株式会社 Preventive or therapeutic agent for respiratory diseases
WO2023157895A1 (en) * 2022-02-17 2023-08-24 国立大学法人 鳥取大学 Prophylactic agent or therapeutic agent for endometriosis or adenomyosis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5534960Y2 (en) 1977-01-31 1980-08-18
JPS53111093A (en) * 1977-03-07 1978-09-28 Takeda Chem Ind Ltd Imidazo(1,5-d)(1,4)benzodiazepin derivative and its preparation
JPH02304437A (en) * 1989-05-19 1990-12-18 Konica Corp Novel photographic coupler
PL180026B1 (en) * 1994-04-14 2000-12-29 Glaxo Wellcome Inc Derivatives of 5-heterocyclo 1,5-benzodiazepine
PE27497A1 (en) 1994-04-15 1997-08-07 Glaxo Inc DERIVATIVES OF 1,5 BENZODIAZEPINA
SE0104250D0 (en) 2001-12-14 2001-12-14 Astrazeneca Ab Heterocyclic compounds
AU2003288352A1 (en) * 2002-10-30 2004-06-07 Centre National De La Recherche Scientifique (Cnrs) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
DE10312969A1 (en) 2003-03-24 2004-10-07 Bayer Healthcare Ag Benzofuro-1,4-diazepin-2-one derivatives
CA2444161A1 (en) 2003-10-01 2005-04-01 Japan Health Sciences Foundation A screening method of drug for treatment of neuropathic pain
KR100512749B1 (en) 2004-01-14 2005-09-07 삼성전자주식회사 Monitor
US20100298285A1 (en) 2006-03-16 2010-11-25 Kelly Michael G Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
WO2008023847A1 (en) 2006-08-25 2008-02-28 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
WO2008100624A2 (en) 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
JP2012087053A (en) * 2009-02-03 2012-05-10 Nippon Chemiphar Co Ltd Diazepinedione derivative
DK2397480T3 (en) * 2009-02-16 2013-09-02 Nippon Chemiphar Co DIAZEPINDION DERIVATIVES
JP5843770B2 (en) * 2010-07-13 2016-01-13 日本ケミファ株式会社 P2X4 receptor antagonist
JP2013209292A (en) * 2010-07-23 2013-10-10 Nippon Chemiphar Co Ltd P2x4 receptor antagonist
CA2840336C (en) * 2011-05-25 2020-06-30 Kyushu University Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
CA2861024C (en) 2012-01-13 2020-09-22 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist

Also Published As

Publication number Publication date
PL2803662T3 (en) 2017-09-29
EP2803662A1 (en) 2014-11-19
CN104066724B (en) 2020-04-17
PT2803662T (en) 2017-04-05
AU2013208536A1 (en) 2014-08-21
WO2013105608A1 (en) 2013-07-18
CA2861024C (en) 2020-09-22
EP2803662B1 (en) 2017-03-01
ES2626036T3 (en) 2017-07-21
US20160280667A1 (en) 2016-09-29
KR20200032762A (en) 2020-03-26
KR20140116926A (en) 2014-10-06
US11434207B2 (en) 2022-09-06
CN111333588A (en) 2020-06-26
SG11201404030YA (en) 2014-10-30
CN104066724A (en) 2014-09-24
JP6207399B2 (en) 2017-10-04
US20140357858A1 (en) 2014-12-04
SG10201605325TA (en) 2016-08-30
IL233592A0 (en) 2014-08-31
US20200223806A1 (en) 2020-07-16
KR102092147B1 (en) 2020-03-23
DK2803662T3 (en) 2017-05-01
HK1203191A1 (en) 2015-10-23
US10633349B2 (en) 2020-04-28
CA2861024A1 (en) 2013-07-18
EP2803662A4 (en) 2015-06-03
CN108863959A (en) 2018-11-23
CN110483423A (en) 2019-11-22
US20220380322A1 (en) 2022-12-01
US20180201587A1 (en) 2018-07-19
AU2013208536B2 (en) 2017-07-20
IL233592B (en) 2018-08-30
KR102140746B1 (en) 2020-08-04
US9382236B2 (en) 2016-07-05
US9969700B2 (en) 2018-05-15
CN108863959B (en) 2021-11-30
JPWO2013105608A1 (en) 2015-05-11

Similar Documents

Publication Publication Date Title
NZ627878A (en) P2x4 receptor antagonist
PH12016501822A1 (en) Cyclopropaneamine compound
PH12016501007A1 (en) Substituted benzamides and methods of use thereof
MY169043A (en) New dihydroquinoline-2-one derivatives
PH12015502232A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
MX2015010775A (en) Substituted benzoxazoles and methods of use thereof.
IN2014MN01897A (en)
MA32731B1 (en) CEPHALOSPORINE HAVING A CATÉCHOL GROUP
MY186165A (en) New bicyclic dihydroquinoline-2-one derivatives
TR201911151T4 (en) Jak2 and alk2 inhibitors and their usage methods.
MX2015001099A (en) New bicyclicpyridine derivatives.
PH12014501540A1 (en) 4-(benzoimidazol-2-yl) - thiazole compounds and related aza derivatives
MY161134A (en) Piperazine compound having a pgds inhibitory effect
PH12015502429A1 (en) Dicarboxylic acid compound
MX344474B (en) Novel furanone derivative.
PH12015501146A1 (en) Hydantoin derivative
MX366678B (en) New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1- one compounds.
MX2015015010A (en) New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1- one compounds.
EA201390374A1 (en) HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OR PREVENTION OF DISORDERS CAUSED BY FACILITATED BY NEUROTREMISSION OF SEROTONIN, NOREPINEFRIN OR DOPAMINE
MX348338B (en) Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds.
MX2014015491A (en) Novel adamantyl derivatives as cannabinoid receptor 2 agonists.
IN2014CN02036A (en)
IN2013MN00506A (en)
MX2017001104A (en) Noxious arthropod control agent containing amide compound.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2018 BY CPA GLOBAL

Effective date: 20161223

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2019 BY CPA GLOBAL

Effective date: 20171130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2020 BY CPA GLOBAL

Effective date: 20181129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2021 BY CPA GLOBAL

Effective date: 20191227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2022 BY CPA GLOBAL

Effective date: 20201203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2023 BY CPA GLOBAL

Effective date: 20211210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2024 BY CPA GLOBAL

Effective date: 20221202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2025 BY CPA GLOBAL

Effective date: 20231130